Tangible resources for preparing patients for antiviral therapy for chronic hepatitis C

Digestive Diseases and Sciences

Volumn 57, Issue 6, 2012, Pages 1439-1444

  Bonner, Jason E ^a   Barritt, A Sidney ^a   Fried, Michael W ^a   Evon, Donna M ^a  

^a UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

Author keywords

Depression; Multidisciplinary; Psychiatric; Substance abuse

Indexed keywords

ANTIVIRAL THERAPY; CLINICAL PRACTICE; COMMUNICATION SKILL; HEALTH SERVICE; HEPATITIS C; HUMAN; INTERVIEW; MEDICAL SPECIALIST; MENTAL HEALTH; MOTIVATION; PATIENT CARE; PATIENT COMPLIANCE; PRACTICE GUIDELINE; PRIORITY JOURNAL; PSYCHIATRIST; PSYCHOSOCIAL CARE; REVIEW; SCREENING; SUBSTANCE ABUSE;

EID: 84864284655     PISSN: 01632116     EISSN: 15732568     Source Type: Journal    
DOI: 10.1007/s10620-012-2142-3     Document Type: Review

References (65)

1. U.S. Food and Drug Administration. FDA approves Victrelis for Hepatitis C [FDA News Release web site]. May 13, 2011. Available at: http://www.fda.gov/ NewsEvents/Newsroom/PressAnnouncements/ucm255390.htm. Accessed 7 June 2011.
2. U.S. Food and Drug Administration. FDA approves Incivek for hepatitis C [FDA News Release web site]. May 23, 2011. Available at: http://www.fda.gov/ NewsEvents/Newsroom/PressAnnouncements/ucm256299.htm. Accessed 20 March 2012.
3. Volk ML. Antiviral therapy for hepatitis C: why are so few patients being treated? J Antimicrob Chemother. 2010;65:1327-1329.
4. Volk ML, Tocco R, Saini S, et al. Public health impact of antiviral therapy for hepatitis C in the United States. Hepatology. 2009;50:1750-1755.
5. Davis GL, Alter MJ, El-Serag H, et al. Aging of hepatitis C virus (HCV)-infected persons in the United States: a multiple cohort model of HCV prevalence and disease progression. Gastroenterology. 2010;138:513-521.
6. Kramer JR, Kanwal F, Richardson P, et al. Importance of patient, provider, and facility predictors of hepatitis C virus treatment in veterans: a national study. Am J Gastroenterol. 2011;106:483-491.
7. Kanwal F, Hoang T, Spiegel BM, et al. Predictors of treatment in patients with chronic hepatitis C infection - role of patient versus nonpatient factors. Hepatology. 2007;46:1741-1749.
8. Stepanova M, Kanwal F, El-Serag HB, et al. Insurance status and treatment candidacy of hepatitis C patients: analysis of population-based data from the United States. Hepatology. 2011;53: 737-745.
9. Evon DM, Verma A, Dougherty KA, et al. High deferral rates and poorer treatment outcomes for HCV patients with psychiatric and substance use comorbidities. Dig Dis Sci. 2007;52: 3251-3258. (Pubitemid 47512531)
10. Muir AJ, Provenzale D. A descriptive evaluation of eligibility for therapy among veterans with chronic hepatitis C virus infection. J Clin Gastroenterol. 2002;34:268-271. (Pubitemid 34177383)
11. Falck-Ytter Y, Kale H, Mullen KD, et al. Surprisingly small effect of antiviral treatment in patients with hepatitis C. Ann Intern Med. 2002;136:288-292. (Pubitemid 34150758)
12. Butt AA, Wagener M, Shakil AO, et al. Reasons for non-treatment of hepatitis C in veterans in care. J Viral Hepat. 2005;12: 81-85. (Pubitemid 40188778)
13. Schaefer M, Schmidt F, Folwaczny C, et al. Adherence and mental side effects during hepatitis C treatment with interferon alfa and ribavirin in psychiatric risk groups. Hepatology. 2003; 37:443-451. (Pubitemid 36152544)
14. Schaefer M, Heinz A, Backmund M. Treatment of chronic hepatitis C in patients with drug dependence: time to change the rules? Addiction. 2004;99:1167-1175. (Pubitemid 39215278)
15. Schaefer M, Schwaiger M, Garkisch AS, et al. Prevention of interferon-alpha associated depression in psychiatric risk patients with chronic hepatitis C. J Hepatol. 2005;42:793-798. (Pubitemid 40693194)
16. Schaefer M, Hinzpeter A, Mohmand A, et al. Hepatitis C treatment in "difficult-to-treat" psychiatric patients with pegylated interferon-alpha and ribavirin: response and psychiatric side effects. Hepatology. 2007;46:991-998. (Pubitemid 350144763)
17. Grebely J, Genoway K, Khara M, et al. Treatment uptake and outcomes among current and former injection drug users receiving directly observed therapy within a multidisciplinary group model for the treatment of hepatitis C virus infection. Int J Drug Policy. 2007;18:437-443. (Pubitemid 47381422)
18. Knott A, Dieperink E, Willenbring ML, et al. Integrated psychiatric/medical care in a chronic hepatitis C clinic: effect on antiviral treatment evaluation and outcomes. Am J Gastroenterol. 2006;101:2254-2262. (Pubitemid 44477552)
19. Sylvestre DL, Loftis JM, Hauser P, et al. Co-occurring Hepatitis C, substance use, and psychiatric illness: treatment issues and developing integrated models of care. J Urban Health. 2004;81:719-734. (Pubitemid 39457952)
20. Sylvestre DL. Treating hepatitis C virus infection in active substance users. Clin Infect Dis. 2005;40:S321-S324. (Pubitemid 40490218)
21. Sylvestre DL, Clements BJ. Adherence to hepatitis C treatment in recovering heroin users maintained on methadone. Eur J Gastroenterol Hepatol. 2007;19:741-747. (Pubitemid 47266701)
22. Matthews G, Kronborg IJ, Dore GJ. Treatment for hepatitis C virus infection among current injection drug users in Australia. Clin Infect Dis. 2005;40:S325-S329. (Pubitemid 40490219)
23. Freedman K, Nathanson J. Interferon-based hepatitis C treatment in patients with pre-existing severe mental illness and substance use disorders. Expert Rev Anti Infect Ther. 2009;7:363-376.
24. Zanini B, Covolo L, Donato F, et al. Effectiveness and tolerability of combination treatment of chronic hepatitis C in illicit drug users: meta-analysis of prospective studies. Clin Ther. 2010;32:2139-2159.
25. Bruggmann P, Falcato L, Dober S, et al. Active intravenous drug use during chronic hepatitis C therapy does not reduce sustained virological response rates in adherent patients. J Viral Hepat. 2008;15:747-752.
26. Bruggmann P, Dampz M, Gerlach T, et al. Treatment outcome in relation to alcohol consumption during hepatitis C therapy: an analysis of the Swiss Hepatitis C Cohort study. Drug Alcohol Depend. 2010;110:167-171.
27. Evon DM, Esserman DA, Rao T, et al. Patient missed doses and treatment non-persistence during PEG/Ribavirin therapy for chronic hepatitis C: implications for triple therapy and beyond. Hepatology. 2011;54:869A.
28. Leutscher PD, Lagging M, Buhl MR, et al. Evaluation of depression as a risk factor for treatment failure in chronic hepatitis C. Hepatology. 2010;52:430-435.
29. Radloff LS. The CES-D scale: a self-report depression scale for research in the general population. Appl Psychol Measurement. 1977;1:385-401.
30. Evon DM, Ramcharran D, Belle SH, et al. Prospective analysis of depression during peginterferon and ribavirin therapy of chronic hepatitis C: results of the VIRAHEP-C study. American Journal of Gastroenterology. 2009;104:2949-2958.
31. Beck AT, Steer RA, Ball R, et al. Comparison of beck depression inventories -IA and -II in psychiatric outpatients. J Pers Assess. 1996;67:588-597. (Pubitemid 26382973)
32. Kroenke K, Spitzer RL, Williams JB. The PHQ-9: validity of a brief depression severity measure. J Gen Intern Med. 2001;16: 606-613. (Pubitemid 32823891)
33. Hirschfeld RM, Williams JB, Spitzer RL, et al. Development and validation of a screening instrument for bipolar spectrum disorder: the Mood Disorder Questionnaire. Am J Psychiatry. 2000; 157:1873-1875.
34. Nassir GS, Miller CJ, Berv DA, et al. Sensitivity and specificity of a new bipolar spectrum diagnostic scale. J Affect Disord. 2005; 84:273-277. (Pubitemid 40222510)
35. Saunders JB, Aasland OG, Babor TF, et al. Development of the alcohol use disorders identification test (AUDIT): WHO collaborative project on early detection of persons with harmful alcohol consumption-II. Addiction. 1993;88:791-804. (Pubitemid 23194530)
36. Yudko E, Lozhkina O, Fouts A. A comprehensive review of the psychometric properties of the Drug Abuse Screening Test. J Subst Abuse Treat. 2007;32:189-198. (Pubitemid 46240723)
37. Sylvestre D. Hepatitis C treatment in drug users: perception versus evidence. Eur J Gastroenterol Hepatol. 2006;18:129-130. (Pubitemid 43361596)
38. Rollnick S, Miller W, Butler C. Motivational Interviewing in Health Care: Helping Patients Change Behavior. New York: The Guilford Press; 2007.
39. Emmons KM, Rollnick S. Motivational interviewing in health care settings. Opportunities and limitations. Am J Prev Med. 2001;20:68-74. (Pubitemid 32013070)
40. Miller WR, Rollnick S. Motivational interviewing: preparing people for change. New York: Guilford Press; 2002.
41. Martins RK, McNeil DW. Review of motivational interviewing in promoting health behaviors. Clin Psychol Rev. 2009;29: 283-293.
42. Knight KM, McGowan L, Dickens C, et al. A systematic review of motivational interviewing in physical health care settings. Br J Health Psychol. 2006;11:319-332. (Pubitemid 43799745)
43. Searight HR. Efficient counseling techniques for the primary care physician. Prim Care. 2007;34:551-570. (Pubitemid 47374777)
44. Lev-Ran S, Nitzan U. Motivational interviewing in health care. Harefuah. 2011;150:749.
45. Callahan EJ, Flynn NM, Kuenneth CA, et al. Strategies to reduce HIV risk behavior in HIV primary care clinics: brief provider messages and specialist intervention. AIDS Behav. 2007;11:S48-S57. (Pubitemid 47319534)
46. Rubak S, Sandbaek A, Lauritzen T, et al. Motivational interviewing: a systematic review and meta-analysis. Br J Gen Pract. 2005;55:305-312. (Pubitemid 40520908)
47. Miller WR. Enhancing motivation for change in substance abuse treatment. Treatment improvement protocol (TIP) series 35. Department of Health and Human Services, Substance Abuse and Mental Health Services Administration, Center for Substance Abuse Treatment. DHHD Publication No. (SMA) 99-3354. Rockville, MD; 1999.
48. Rifai MA, Moles JK, Lehman LP, et al. Hepatitis C screening and treatment outcomes in patients with substance use/dependence disorders. Psychosomatics. 2006;47:112-121. (Pubitemid 43346958)
49. Dieperink E, Ho SB, Heit S, et al. Significant reductions in drinking following brief alcohol treatment provided in a hepatitis C clinic. Psychosomatics. 2010;51:149-156.
50. Berg CJ, Michelson SE, Safren SA. Behavioral aspects of HIV care: adherence, depression, substance use, and HIV-transmission behaviors. Infect Dis Clin North Am. 2007;21:181-200. (Pubitemid 46729632)
51. Golin C, Isasi F, Bontempi JB, et al. Secret pills: HIV-positive patients' experiences taking antiretroviral therapy in North Carolina. AIDS Educ Prev. 2002;14:318-329. (Pubitemid 34977108)
52. Haynes RB, Ackloo E, Sahota N, et al. Interventions for enhancing medication adherence. Cochrane Database Syst Rev. 2008;CD000011.
53. Hendershot CS, Stoner SA, Pantalone DW, et al. Alcohol use and antiretroviral adherence: review and meta-analysis. J Acquir Immune Defic Syndr. 2009;52:180-202.
54. McHutchison JG, Manns M, Patel K, et al. Adherence to combination therapy enhances sustained response in genotype-1-infected patients with chronic hepatitis C. Gastroenterology. 2002;123: 1061-1069.
55. Martin-Santos R, Diez-Quevedo C, Castellvi P, et al. De novo depression and anxiety disorders and influence on adherence during peginterferon-alpha-2a and ribavirin treatment in patients with hepatitis C. Aliment Pharmacol Ther. 2008;27:257-265.
56. Paterson DL, Swindells S, Mohr J, et al. Adherence to protease inhibitor therapy and outcomes in patients with HIV infection. Ann Intern Med. 2000;133:21-30. (Pubitemid 30432540)
57. Weiden PJ. The adherence interview: Better information, better alliance. Psychiatric Annals Online, 2011; 41 (online only). Available at: http://www.psychiatricannalsonline.com/view.asp?rID=84071. Accessed 15 June 2011.
58. Hill S, Kavookjian J. Motivational interviewing as a behavioral intervention to increase HAART adherence in patients who are HIV-positive: a systematic review of the literature. AIDS Care. (Epub ahead of print). doi:10.1080/09540121.2011.630354.
59. Zolnierek KB, Dimatteo MR. Physician communication and patient adherence to treatment: a meta-analysis. Med Care. 2009;47:826-834.
60. Martin LR, Williams SL, Haskard KB, et al. The challenge of patient adherence. Ther Clin Risk Manag. 2005;1:189-199.
61. Tanioka D, Iwasaki Y, Araki Y, et al. Factors associated with adherence to combination therapy of interferon and ribavirin for patients with chronic hepatitis C: importance of patient's motivation and physician's treatment experience. Liver Int. 2009;29: 721-729.
62. Simoni JM, Amico KR, Pearson CR, et al. Strategies for promoting adherence to antiretroviral therapy: a review of the literature. Curr Infect Dis Rep. 2008;10:515-521.
63. Golin CE, Liu H, Hays RD, et al. A prospective study of predictors of adherence to combination antiretroviral medication. J Gen Intern Med. 2002;17:756-765. (Pubitemid 35286241)
64. Vezali E, Aghemo A, Colombo M. Interferon in the treatment of chronic hepatitis C: a drug caught between past and future. Expert Opin Biol Ther. 2011;11:301-313.
65. Kanwal F, Hoang T, Kramer JR, et al. Increasing prevalence of HCC and cirrhosis in patients with chronic hepatitis C virus infection. Gastroenterology. 2011;140:1182-1188.